Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan.
Institute for Integrated Medical Sciences, Tokyo Women's Medical University, Tokyo, Japan.
J Hepatobiliary Pancreat Sci. 2017 Aug;24(8):456-465. doi: 10.1002/jhbp.481. Epub 2017 Jul 3.
The clinical relevance of a high-grade dysplasia/carcinoma in situ (HD/CIS)-positive bile duct margin in perihilar cholangiocarcinoma (PHC) is unclear. We evaluated the surgical outcomes of PHC patients with HD/CIS.
Clinicopathological data of 163 consecutive patients who underwent resection of PHC between 2004 and 2013 were analyzed retrospectively.
Postoperative states included curative resection (R0) with free margins in 113 patients, non-curative resection with HD/CIS (R1-HD/CIS) in 22 patients, and non-curative resection with any invasive carcinoma margin in 28 patients. Multivariate analyses in the entire cohort showed that lymph node metastasis (hazard ratio [HR] 1.91), distant metastasis (HR 3.87), and non-curative resection with any invasive carcinoma margin (vs. R0; HR 2.06) were significant independent prognosticators. However, in node-negative and distant metastasis-negative PHC patients, histology (HR 2.97), R1-HD/CIS (vs. R0; HR 2.31), and non-curative resection with any invasive carcinoma margin (vs. R0; HR 5.33) were significant independent prognosticators. The 2- and 5-year disease-specific survival rates in node-negative and distant metastasis-negative PHC patients with R1-HD/CIS margins were lower compared with those in patients with R0 margins (2-year, 76.7% vs. 84.3%; 5-year, 37.5% vs. 69.3%; P = 0.026).
R1-HD/CIS should be avoided in patients undergoing surgery for node-negative and distant metastasis-negative PHC.
高位异型增生/原位癌(HD/CIS)阳性胆管切缘在肝门周围胆管癌(PHC)中的临床意义尚不清楚。我们评估了 PHCC 患者 HD/CIS 的手术结果。
回顾性分析了 2004 年至 2013 年间 163 例连续接受 PHC 切除术患者的临床病理资料。
术后状态包括 113 例无瘤切缘的根治性切除术(R0)、22 例有 HD/CIS(R1-HD/CIS)的非根治性切除术和 28 例有任何浸润性癌切缘的非根治性切除术。全队列多变量分析显示,淋巴结转移(风险比[HR]1.91)、远处转移(HR3.87)和任何浸润性癌切缘的非根治性切除术(与 R0 相比;HR2.06)是显著的独立预后因素。然而,在淋巴结阴性和远处转移阴性的 PHC 患者中,组织学(HR2.97)、R1-HD/CIS(与 R0 相比;HR2.31)和任何浸润性癌切缘的非根治性切除术(与 R0 相比;HR5.33)是显著的独立预后因素。R1-HD/CIS 边缘的淋巴结阴性和远处转移阴性 PHC 患者的 2 年和 5 年疾病特异性生存率低于 R0 边缘的患者(2 年,76.7% vs.84.3%;5 年,37.5% vs.69.3%;P=0.026)。
对于淋巴结阴性和远处转移阴性的 PHC 患者,应避免行 R1-HD/CIS。